Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) EPS (Basic) (2020 - 2026)

Opus Genetics has reported EPS (Basic) over the past 12 years, most recently at -$0.75 for Q1 2026.

  • Quarterly EPS (Basic) fell 212.5% to -$0.75 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.33 through Mar 2026, up 36.67% year-over-year, with the annual reading at -$0.8 for FY2025, 62.79% up from the prior year.
  • EPS (Basic) was -$0.75 for Q1 2026 at Opus Genetics, down from -$0.21 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.72 in Q4 2022 and troughed at -$1.27 in Q4 2024.
  • The 5-year median for EPS (Basic) is -$0.25 (2022), against an average of -$0.19.
  • Year-over-year, EPS (Basic) skyrocketed 1055.56% in 2022 and then plummeted 504.76% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at $1.72 in 2022, then tumbled by 112.21% to -$0.21 in 2023, then plummeted by 504.76% to -$1.27 in 2024, then skyrocketed by 83.46% to -$0.21 in 2025, then crashed by 257.14% to -$0.75 in 2026.
  • Per Business Quant, the three most recent readings for IRD's EPS (Basic) are -$0.75 (Q1 2026), -$0.21 (Q4 2025), and -$0.25 (Q3 2025).